{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:56:06Z","timestamp":1789012566937,"version":"build-2803163510"},"reference-count":138,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006595","name":"Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii","doi-asserted-by":"publisher","award":["PN-III-P1-1.1-PD-2019-1225"],"award-info":[{"award-number":["PN-III-P1-1.1-PD-2019-1225"]}],"id":[{"id":"10.13039\/501100006595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Colorectal cancer (CRC) is an important public health issue, in terms of incidence and mortality, with approximately 1.8 million new cases reported worldwide in 2018. Advancements in understanding pathophysiological key steps in CRC tumorigenesis have led to the development of new targeted therapies such as those based on epidermal growth factor receptor inhibitors (EGFR inhibitors). The cutaneous adverse reactions induced by EGFR inhibitors, particularly papulopustular rash, often require long-term antibiotic treatment with tetracycline agents (mostly minocycline and doxycycline). However, this raises several issues of concern: possible occurrence of gut dysbiosis in already vulnerable CRC patients, selection of highly antibiotic resistant and\/or virulent clones, development of adverse reactions related to tetracyclines, interference of antibiotics with the response to oncologic therapy, with a negative impact on disease prognosis etc. In the context of scarce information regarding these issues and controversial opinions regarding the role of tetracyclines in patients under EGFR inhibitors, our aim was to perform a thorough literature review and discuss the main challenges raised by long-term use of tetracyclines in advanced CRC patients receiving this targeted therapy.<\/jats:p>","DOI":"10.3390\/jcm10153219","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T11:53:23Z","timestamp":1626868403000},"page":"3219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-0088","authenticated-orcid":false,"given":"Mara M\u0103d\u0103lina","family":"Mihai","sequence":"first","affiliation":[{"name":"Department of Oncologic Dermatology, \u2018Elias\u2019 Emergency University Hospital, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"},{"name":"Department of Microbiology, Faculty of Biology, ICUB\u2014Research Institute of the University of Bucharest, 050657 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ion","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103lin","family":"Giurc\u0103neanu","sequence":"additional","affiliation":[{"name":"Department of Oncologic Dermatology, \u2018Elias\u2019 Emergency University Hospital, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Ni\u021bipir","sequence":"additional","affiliation":[{"name":"Department of Oncology, \u2018Elias\u2019 Emergency University Hospital, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Oncology, \u2018Elias\u2019 Emergency University Hospital, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-1857","authenticated-orcid":false,"given":"Mariana-Carmen","family":"Chifiriuc","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Biology, ICUB\u2014Research Institute of the University of Bucharest, 050657 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-9329","authenticated-orcid":false,"given":"Mircea Ioan","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"\u0158\u00ed\u010da\u0159","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Charles University, Medical School and Teaching Hospital Pilsen, 30599 Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana Gabriela","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Oncologic Dermatology, \u2018Elias\u2019 Emergency University Hospital, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-0846","authenticated-orcid":false,"given":"Ionela","family":"S\u00e2rbu","sequence":"additional","affiliation":[{"name":"Department of Genetics, Faculty of Biology, ICUB\u2014Research Institute of the University of Bucharest, 050657 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Laz\u0103r","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Biology, ICUB\u2014Research Institute of the University of Bucharest, 050657 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"ref_3","first-page":"Cd007047","article-title":"Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer","volume":"6","author":"Chan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40487-017-0050-6","article-title":"EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management","volume":"5","author":"Guggina","year":"2017","journal-title":"Oncol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.2011-0365","article-title":"Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: A systematic literature review","volume":"17","author":"Bachet","year":"2012","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: Systemic review and meta-analysis","volume":"77","author":"Su","year":"2009","journal-title":"Oncology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"734249","DOI":"10.1155\/2014\/734249","article-title":"Epidermal growth factor receptor inhibitors: A review of cutaneous adverse events and management","volume":"2014","author":"Chanprapaph","year":"2014","journal-title":"Dermatol. Res. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.616","article-title":"Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000088502","article-title":"Cetuximab-induced acne","volume":"211","author":"Molinari","year":"2005","journal-title":"Dermatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","article-title":"Management of dermatologic adverse events from cancer therapies: Recommendations of an expert panel","volume":"95","author":"Eris","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-019-03927-x","article-title":"Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study","volume":"84","author":"Rothschild","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"105061","DOI":"10.18632\/oncotarget.21249","article-title":"AIO LQ-0110: A randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer","volume":"8","author":"Kripp","year":"2017","journal-title":"Oncotarget"},{"key":"ref_16","unstructured":"Albertha Health Services (2012). Prevention and treatment of acneiform rash in patients treated with EGFR inhibitor therapies. Clin. Pract. Guidel., Available online: https:\/\/www.albertahealthservices.ca\/assets\/info\/hp\/cancer\/if-hp-cancer-guide-supp003-egfri-rash.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","article-title":"Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors","volume":"21","author":"Hofheinz","year":"2016","journal-title":"Oncologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1073\/pnas.95.26.15769","article-title":"Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia","volume":"95","author":"Pellikka","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","first-page":"672","article-title":"Angiogenesis inhibition by minocycline","volume":"51","author":"Tamargo","year":"1991","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracyclines: Nonantibiotic properties and their clinical implications","volume":"54","author":"Sapadin","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lab.2003.12.012","article-title":"Doxycycline inhibits cell proliferation and invasive potential: Combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells","volume":"143","author":"Onoda","year":"2004","journal-title":"J. Lab. Clin. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0959-8049(03)00235-1","article-title":"Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs","volume":"39","author":"Ciardiello","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40265-019-01113-0","article-title":"Targeting EGFR and RAS\/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives","volume":"79","author":"Mizukami","year":"2019","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00145363","article-title":"Atherogenic profiles in insulin-dependent diabetic patients and their treatment","volume":"8","year":"1992","journal-title":"Eur. J. Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2007.02.006","article-title":"Cellular responses to EGFR inhibitors and their relevance to cancer therapy","volume":"254","author":"Dutta","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Miyamoto, Y., Suyama, K., and Baba, H. (2017). Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040752"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.3816\/CCC.2005.s.010","article-title":"Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer","volume":"5","author":"Snyder","year":"2005","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Folprecht","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrg758","article-title":"Getting under the skin of epidermal morphogenesis","volume":"3","author":"Fuchs","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-4632.2011.05082.x","article-title":"The management of EGFR inhibitor adverse events: A case series and treatment paradigm","volume":"51","author":"Wnorowski","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00520-015-2781-y","article-title":"Xerosis and pruritus as major EGFRI-associated adverse events","volume":"24","author":"Clabbers","year":"2016","journal-title":"Support Care Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40261-019-00811-7","article-title":"Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer","volume":"39","author":"Annunziata","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-7819-7-2","article-title":"Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?","volume":"7","author":"Sagar","year":"2009","journal-title":"World J. Surg. Oncol."},{"key":"ref_49","first-page":"1617","article-title":"Doxycycline as Potential Anti-cancer Agent","volume":"17","author":"Ali","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_51","first-page":"6175","article-title":"Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients","volume":"35","author":"Yamada","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP","volume":"11","author":"Kobayashi","year":"2015","journal-title":"Future Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00520-010-0988-5","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3816\/CCC.2008.n.007","article-title":"Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic\/dermatologic cooperation","volume":"7","author":"Racca","year":"2008","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_56","first-page":"129","article-title":"Safety and efficacy of doxycycline in the treatment of rosacea","volume":"2","author":"Morales","year":"2009","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"581","DOI":"10.14219\/jada.archive.2008.0218","article-title":"Recognizing doxycycline-induced esophageal ulcers in dental practice: A case report and review","volume":"139","author":"Segelnick","year":"2008","journal-title":"J. Am. Dent. Assoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: A systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2230.1993.tb02242.x","article-title":"Phototoxic eruptions due to doxycycline--a dose-related phenomenon","volume":"18","author":"Layton","year":"1993","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.7.5.571","article-title":"The use and safety of doxycycline hyclate and other second-generation tetracyclines","volume":"7","author":"Sloan","year":"2008","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJM198503283121307","article-title":"Hemolytic anemia after tetracycline therapy","volume":"312","author":"Simpson","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1525-1470.1999.00106.x","article-title":"Complications of minocycline therapy for acne vulgaris: Case reports and review of the literature","volume":"16","author":"Somech","year":"1999","journal-title":"Pediatr. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The Human Intestinal Microbiome in Health and Disease","volume":"375","author":"Lynch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40168-019-0747-x","article-title":"A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals","volume":"7","author":"Scepanovic","year":"2019","journal-title":"Microbiome"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.1038\/ncomms9727","article-title":"Gut mucosal microbiome across stages of colorectal carcinogenesis","volume":"6","author":"Nakatsu","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000323926","article-title":"Colon cancer: A civilization disorder","volume":"29","author":"Watson","year":"2011","journal-title":"Dig. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chom.2013.07.012","article-title":"Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin\/\u03b2-catenin signaling via its FadA adhesin","volume":"14","author":"Rubinstein","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","article-title":"Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment","volume":"14","author":"Kostic","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15354","DOI":"10.1073\/pnas.1010203108","article-title":"Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis","volume":"108","author":"Goodwin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nm.2015","article-title":"A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses","volume":"15","author":"Wu","year":"2009","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.gastro.2016.11.018","article-title":"Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-\u03baB, and Up-regulating Expression of MicroRNA-21","volume":"152","author":"Yang","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Clos-Garcia, M., Garcia, K., Alonso, C., Iruarrizaga-Lejarreta, M., D\u2019Amato, M., Crespo, A., Iglesias, A., Cubiella, J., Bujanda, L., and Falc\u00f3n-P\u00e9rez, J.M. (2020). Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers, 12.","DOI":"10.2139\/ssrn.3520024"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fmicb.2020.00814","article-title":"Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway","volume":"11","author":"Xu","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3748\/wjg.v22.i2.501","article-title":"Gut microbiota imbalance and colorectal cancer","volume":"22","author":"Raisch","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Alhinai, E.A., Walton, G.E., and Commane, D.M. (2019). The Role of the Gut Microbiota in Colorectal Cancer Causation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215295"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"31802","DOI":"10.18632\/oncotarget.15992","article-title":"Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4\/P-PAK1 cascade","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.immuni.2015.01.010","article-title":"Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack","volume":"42","author":"Gur","year":"2015","journal-title":"Immunity"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1101\/gr.126573.111","article-title":"Genomic analysis identifies association of Fusobacterium with colorectal carcinoma","volume":"22","author":"Kostic","year":"2012","journal-title":"Genome Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/gutjnl-2015-309800","article-title":"Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer","volume":"66","author":"Yu","year":"2017","journal-title":"Gut"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1126\/science.aal5240","article-title":"Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer","volume":"358","author":"Bullman","year":"2017","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e17221","DOI":"10.1097\/MD.0000000000017221","article-title":"Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41416-020-01198-5","article-title":"Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma","volume":"124","author":"Liu","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_84","unstructured":"Gilbert, D.N., Chambers, H.F., Saag, M.S., Pavia, A.T., Black, D., Boucher, H.W., Freedman, D.O., Kim, K., and Scwartz, B.S. (2020). The Sanford Guide to Antimicrobial Therapy 2020-Pocket Edition, Antimicrobial Therapy, Inc.. [50th ed.]."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jmii.2020.03.027","article-title":"Lemierre\u2019s syndrome: A forgotten and re-emerging infection","volume":"53","author":"Lee","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1080\/19490976.2020.1764309","article-title":"Therapeutic methods of gut microbiota modification in colorectal cancer management-fecal microbiota transplantation, prebiotics, probiotics, and synbiotics","volume":"11","author":"Daca","year":"2020","journal-title":"Gut Microbes"},{"key":"ref_87","first-page":"4131","article-title":"A technology of experimental studies on the xenobiotic element sorption characteristics of representatives of the intestinal normal flora","volume":"9","author":"Sizentsov","year":"2019","journal-title":"Bioint. Res. App. Chem."},{"key":"ref_88","first-page":"4830","article-title":"Effectiveness of combined use of antibiotics, essential metals and probiotic bacterial strain complexes against multidrug resistant pathogens","volume":"10","author":"Sizentsov","year":"2020","journal-title":"Bioint. Res. App. Chem."},{"key":"ref_89","first-page":"4327","article-title":"Formulation strategies for the oral delivery of probiotics: A review","volume":"9","author":"Thakur","year":"2019","journal-title":"Bioint. Res. App. Chem."},{"key":"ref_90","first-page":"4066","article-title":"Possible methods for evaluation of hydrogen sulfide toxicity against lactic acid bacteria","volume":"9","author":"Kushkevych","year":"2019","journal-title":"Bioint. Res. App. Chem."},{"key":"ref_91","first-page":"6058","article-title":"A review on production of exopolysaccharide and biofilm in probiotics like lactobacilli and methods of analysis","volume":"10","author":"Hooshdar","year":"2020","journal-title":"Bioint. Res. App. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamaoncol.2016.6374","article-title":"Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2017.08.019","article-title":"Intermittent Fasting Promotes White Adipose Browning and Decreases Obesity by Shaping the Gut Microbiota","volume":"26","author":"Li","year":"2017","journal-title":"Cell Metab."},{"key":"ref_94","first-page":"2061","article-title":"Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides","volume":"16","author":"Hao","year":"2015","journal-title":"APJCP"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1079\/NRR200484","article-title":"The effects of probiotics on colon cancer development","volume":"17","author":"Rafter","year":"2004","journal-title":"Nutr. Res. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Calu, V., Toma, E.A., Enciu, O., and Miron, A. (2019). Clostridium difficile Infection and Colorectal Surgery: Is There Any Risk?. Medicina, 55.","DOI":"10.3390\/medicina55100683"},{"key":"ref_97","first-page":"248","article-title":"Pyoderma gangrenosum, rare parietal complication after colorectal surgery","volume":"109","author":"Miron","year":"2014","journal-title":"Chirurgia"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Uccello, M., Malaguarnera, G., Basile, F., D\u2019Agata, V., Malaguarnera, M., Bertino, G., Vacante, M., Drago, F., and Biondi, A. (2012). Potential role of probiotics on colorectal cancer prevention. BMC Surg., 12.","DOI":"10.1186\/1471-2482-12-S1-S35"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ijc.25011","article-title":"The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition","volume":"127","author":"Ma","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1007\/s00268-015-3071-z","article-title":"A Four-Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"39","author":"Kotzampassi","year":"2015","journal-title":"World J. Surg."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jff.2014.10.029","article-title":"Galacto-oligosaccharides and Colorectal Cancer: Feeding our Intestinal Probiome","volume":"12","year":"2015","journal-title":"J. Funct. Foods"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ijc.32003","article-title":"Fecal microbiota transplantation in cancer management: Current status and perspectives","volume":"145","author":"Chen","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1128\/AAC.02437-14","article-title":"Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment","volume":"58","author":"Angelakis","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e035677","DOI":"10.1136\/bmjopen-2019-035677","article-title":"Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: A systematic review","volume":"10","author":"Elvers","year":"2020","journal-title":"BMJ Open"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5021\/ad.2020.32.1.21","article-title":"Minocycline and Its Impact on Microbial Dysbiosis in the Skin and Gastrointestinal Tract of Acne Patients","volume":"32","author":"Thompson","year":"2020","journal-title":"Ann. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jinf.2019.10.008","article-title":"The effect of antibiotics on the composition of the intestinal microbiota-a systematic review","volume":"79","author":"Zimmermann","year":"2019","journal-title":"J. Infect."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e01693-15","DOI":"10.1128\/mBio.01693-15","article-title":"Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces","volume":"6","author":"Zaura","year":"2015","journal-title":"mBio"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/47.3.277","article-title":"Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals","volume":"47","author":"Laurent","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_109","first-page":"3834","article-title":"Alternative strategies for fighting multidrug resistant bacterial infections","volume":"9","author":"Podgoreanu","year":"2019","journal-title":"Bioint. Res. App. Chem."},{"key":"ref_110","first-page":"4699","article-title":"Prevalence of vancomycin resistance phenotypes among Enterococcus species isolated from clinical samples in a Romanian hospital","volume":"9","author":"Ducu","year":"2019","journal-title":"Bioint. Res. App. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/s41467-020-18134-z","article-title":"Entropy of a bacterial stress response is a generalizable predictor for fitness and antibiotic sensitivity","volume":"11","author":"Zhu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/s41591-019-0650-9","article-title":"Simultaneous detection of genotype and phenotype enables rapid and accurate antibiotic susceptibility determination","volume":"25","author":"Bhattacharyya","year":"2019","journal-title":"Nat. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1038\/s41598-018-29707-w","article-title":"RNA markers enable phenotypic test of antibiotic susceptibility in Neisseria gonorrhoeae after 10\u2009minutes of ciprofloxacin exposure","volume":"8","author":"Khazaei","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/ijc.23622","article-title":"Antibiotic use predicts an increased risk of cancer","volume":"123","author":"Kilkkinen","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10620-015-3828-0","article-title":"Frequent Use of Antibiotics Is Associated with Colorectal Cancer Risk: Results of a Nested Case-Control Study","volume":"61","author":"Dik","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1136\/gutjnl-2019-318593","article-title":"Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: A matched case-control study","volume":"68","author":"Zhang","year":"2019","journal-title":"Gut"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Lu, L., Zhuang, T., Shao, E., Liu, Y., He, H., Shu, Z., Huang, Y., Yao, Y., Lin, S., and Lin, S. (2019). Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221964"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.02.047","article-title":"Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy","volume":"131","author":"Nenclares","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/EDBK_200821","article-title":"Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management","volume":"38","author":"Overman","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000277430","article-title":"Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: A case series and a literature review of therapeutic approaches","volume":"220","author":"Nikolaou","year":"2010","journal-title":"Dermatology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","article-title":"A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption","volume":"61","author":"Scope","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clcc.2013.10.001","article-title":"Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer","volume":"13","author":"Pinta","year":"2014","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1684\/ejd.2012.1899","article-title":"Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer","volume":"23","author":"Jo","year":"2013","journal-title":"Eur. J. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40257-020-00539-7","article-title":"BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors","volume":"21","author":"Wang","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Lacouture, M.E., Wainberg, Z.A., Patel, A.B., Anadkat, M.J., Stemmer, S.M., Shacham-Shmueli, E., Medina, E., Zelinger, G., Shelach, N., and Ribas, A. (2021). Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. Cancer Discov.","DOI":"10.1158\/2159-8290.CD-20-1847"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jaad.2020.09.090","article-title":"Choosing between isotretinoin and acitretin for epidermal growth factor receptor inhibitor and small molecule tyrosine kinase inhibitor acneiform eruptions","volume":"84","author":"Costello","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaad.2019.10.003","article-title":"A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions","volume":"82","author":"Andrews","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jdcr.2020.07.021","article-title":"Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib","volume":"6","author":"Caruana","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/jamaoncol.2015.1377","article-title":"Fusobacterium nucleatum and T Cells in Colorectal Carcinoma","volume":"1","author":"Mima","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Biagi, E., Nylund, L., Candela, M., Ostan, R., Bucci, L., Pini, E., Nikk\u00efla, J., Monti, D., Satokari, R., and Franceschi, C. (2010). Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE, 5.","DOI":"10.1371\/annotation\/df45912f-d15c-44ab-8312-e7ec0607604d"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/ismej.2010.118","article-title":"Dominant and diet-responsive groups of bacteria within the human colonic microbiota","volume":"5","author":"Walker","year":"2011","journal-title":"ISME J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chom.2019.05.005","article-title":"Daily Sampling Reveals Personalized Diet-Microbiome Associations in Humans","volume":"25","author":"Johnson","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","article-title":"Role of the normal gut microbiota","volume":"21","author":"Jandhyala","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1468-3083.2009.03490.x","article-title":"Cetuximab-induced cutaneous toxicity","volume":"24","author":"Kohoutek","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cam4.2673","article-title":"Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/15\/3219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:33:03Z","timestamp":1760164383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/15\/3219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":138,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jcm10153219"],"URL":"https:\/\/doi.org\/10.3390\/jcm10153219","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]}}}